Announcements Trials
Browse Landscape

Phase

Phase NA 10Phase 2 6Phase 3 4

Status

Terminated 6Recruiting 6Active not recruiting 6Completed 3Withdrawn 2Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Lymphedema 1Carcinoma, Lobular 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Mastectomy, Segmental × Clear all
NCT07053085 2026-05-14

A Study of Surgery and Radiotherapy in People With Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
178 enrolled
Breast

Breast Neoplasms

NCT06092892 2026-05-11

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

Cedars-Sinai Medical Center

Phase 2 Recruiting
45 enrolled
Breast

Breast Neoplasms, Lymphedema

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
53 enrolled
Breast

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

University of Chicago

Phase 2 Recruiting
85 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
30 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡